Immatics Biotechnologies GmbH
Records under this name other than the patents Immatics Biotechnologies GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 476 patents it holds.
Back to Immatics Biotechnologies GmbH
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,513,547 | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers In force · High confidence | In force | High confidence | |
| US 12,312,412 | MAGEB2 Binding Constructs now held by Amgen Research (Munich) GmbH In force · High confidence | In force | High confidence | |
| US 7,807,642 | Tumor-Associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules Term ended Term ended Nov 17, 2026 · High confidence | Term ended | Term ended Nov 17, 2026 | High confidence |
| US 10,196,432 | Tumor-Associated Peptides Binding to Human Leukocyte Antigen (HLA) Class II Molecules Term ended Term ended Nov 17, 2026 · High confidence | Term ended | Term ended Nov 17, 2026 | High confidence |
| US 10,105,428 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers Lapsed on the fee record Ended Oct 23, 2026 · Low confidence | Lapsed on the fee record | Ended Oct 23, 2026 | Low confidence |
| US 10,106,593 | Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors Lapsed on the fee record Ended Oct 23, 2026 · Low confidence | Lapsed on the fee record | Ended Oct 23, 2026 | Low confidence |
| US 10,106,594 | Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors Lapsed on the fee record Ended Oct 23, 2026 · Low confidence | Lapsed on the fee record | Ended Oct 23, 2026 | Low confidence |
| US 7,811,828 | Method for Identifying and Quantifying of Tumour-Associated Term ended Term ended Oct 16, 2026 · Medium confidence | Term ended | Term ended Oct 16, 2026 | Medium confidence |
| US 10,098,937 | Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Cancers Lapsed on the fee record Ended Oct 16, 2026 · Low confidence | Lapsed on the fee record | Ended Oct 16, 2026 | Low confidence |
| US 10,098,938 | Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Cancers Lapsed on the fee record Ended Oct 16, 2026 · Low confidence | Lapsed on the fee record | Ended Oct 16, 2026 | Low confidence |